What Are the Key Safety Warnings for Zepbound (Tirzepatide)?

Boxed Warning: Thyroid C-Cell Tumors

Zepbound's most prominent safety signal is its FDA boxed warning for thyroid C-cell tumors, the strongest alert category the agency assigns. In preclinical studies, tirzepatide caused dose-dependent increases in thyroid C-cell tumors (including medullary thyroid carcinoma) in both male and female rats exposed for the duration of their lifespan [1].

Why the Rodent Signal Matters

The mechanism behind this signal relates to GLP-1 receptor activation on thyroid C-cells. Rodent thyroid C-cells express GLP-1 receptors at much higher density than human C-cells, which means the rodent finding may not directly translate to human risk [2]. The FDA prescribing information states: "It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" [1].

Who Should Not Take Zepbound

The drug is contraindicated in two populations: patients with a personal or family history of MTC, and patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1]. Prescribers should counsel patients about this risk and advise them to report symptoms such as a neck mass, dysphagia, dyspnea, or persistent hoarseness.

Monitoring Calcitonin Levels

Routine serum calcitonin monitoring has not been shown to reduce MTC risk in the general population, and the FDA label does not recommend it as a standard screening measure [1]. The Endocrine Society notes that calcitonin monitoring "is of uncertain value in patients treated with GLP-1 receptor agonists" [3]. Clinicians should use clinical judgment when deciding whether to check calcitonin in individual patients.

Acute Pancreatitis

Acute pancreatitis was reported in clinical trials of tirzepatide, including events that required hospitalization. In the SURMOUNT-1 trial (N=2,539), pancreatitis occurred in a small number of participants across all dose groups, though rates were low overall [4].

Recognizing the Warning Signs

Patients should be educated to recognize signs of pancreatitis: severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. The FDA label directs prescribers to discontinue Zepbound promptly if pancreatitis is suspected and not restart it if pancreatitis is confirmed [1].

Risk Factors That Compound the Danger

A history of pancreatitis is not listed as a formal contraindication, but it warrants caution. Patients with a history of alcohol use disorder, hypertriglyceridemia (triglycerides >500 mg/dL), or gallstone disease carry additive risk. The American Gastroenterological Association recommends that clinicians weigh the benefits of GLP-1 receptor agonist therapy against pancreatic risk in these patients on an individual basis [5].

Gallbladder Events

Gallbladder-related adverse events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), occurred at higher rates in tirzepatide-treated patients than in placebo groups across the SURMOUNT trial program [1].

Why Rapid Weight Loss Triggers Gallstones

Rapid weight loss is a well-established risk factor for gallstone formation. When the body metabolizes fat stores quickly, the liver secretes excess cholesterol into bile, supersaturating it and promoting stone crystallization [6]. In SURMOUNT-1, participants on the 15 mg dose lost a mean of 22.5% of body weight at 72 weeks [4]. That degree of weight reduction, while clinically meaningful, creates a metabolic environment favorable to cholelithiasis.

Clinical Approach to Gallbladder Monitoring

The FDA label recommends informing patients about the signs and symptoms of gallbladder disease. Right upper quadrant pain, food intolerance (particularly fatty meals), nausea after eating, and fever with jaundice should prompt evaluation with right upper quadrant ultrasound and liver function tests. If acute cholecystitis is confirmed, Zepbound should be discontinued pending surgical consultation [1].

Acute Kidney Injury

Reports of acute kidney injury (AKI) have occurred in patients taking GLP-1 receptor agonists, including tirzepatide. Most reported cases were associated with dehydration secondary to gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea [1].

The Dehydration Pathway

The nausea and vomiting that affect up to one-third of patients in the early weeks of tirzepatide therapy can reduce oral fluid intake significantly [4]. When combined with diarrhea, this creates a volume depletion state that compromises renal perfusion. Patients on concurrent nephrotoxic medications or those with pre-existing chronic kidney disease (eGFR <60 mL/min/1.73 m²) face heightened risk [7].

Practical Prevention Strategies

Clinicians should advise patients to maintain adequate hydration, especially during dose escalation when GI side effects peak. Monitoring renal function (serum creatinine, BUN) at baseline and during dose titration is reasonable in patients with risk factors. The prescribing information recommends considering dose reduction or temporary discontinuation if significant GI symptoms develop in patients with renal impairment [1].

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with tirzepatide. In clinical trials, hypersensitivity events (such as urticaria, facial edema, and anaphylactic reactions) occurred in some participants [1].

When to Discontinue Permanently

Zepbound is contraindicated in patients with known serious hypersensitivity to tirzepatide or any of its excipients. If a patient experiences signs or symptoms of anaphylaxis or severe hypersensitivity, the drug must be discontinued permanently and not restarted [1]. Mild injection-site reactions (erythema, pruritus, pain at the injection site) are common and do not necessarily require discontinuation.

Suicidal Ideation and Behavior

The FDA requires monitoring for suicidal ideation and behavior in patients taking Zepbound. The 2024 FDA safety communication noted that the agency was evaluating reports of suicidal thoughts and self-harm in patients using GLP-1 receptor agonists, though a causal relationship had not been established [8].

What the Data Show So Far

A large pharmacovigilance study published in Nature Medicine in 2024 analyzed electronic health records of over 240,000 patients taking semaglutide and found no increased risk of suicidal ideation compared to matched controls [9]. Data specifically for tirzepatide are more limited. In the SURMOUNT trials, psychiatric adverse events were collected but not systematically adjudicated for suicidality [4].

Screening Recommendations

The FDA label advises prescribers to monitor patients for the emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior [1]. Patients with a pre-existing history of depression or suicidal ideation should be monitored closely, particularly during initiation and dose changes. Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "We should screen patients for mental health concerns before starting any anti-obesity medication, and continue monitoring throughout treatment" [10].

Diabetic Retinopathy Complications

Although Zepbound is approved for weight management (not diabetes), some patients using it will have concurrent type 2 diabetes. Rapid improvements in glycemic control have been associated with worsening of diabetic retinopathy, a phenomenon observed with GLP-1 receptor agonists in the SUSTAIN-6 trial of semaglutide [11].

Who Needs Ophthalmologic Monitoring

The FDA label notes that patients with a history of diabetic retinopathy should be monitored for progression of the condition [1]. A baseline dilated eye exam before initiating Zepbound is reasonable in patients with diabetes and any history of retinopathy. The American Diabetes Association 2024 Standards of Care recommend that patients with pre-existing retinopathy undergo more frequent eye examinations when starting therapies that produce rapid HbA1c reductions [12].

Gastrointestinal Side Effects: The Most Common Safety Concern

While not classified as "warnings" in the same regulatory sense as the items above, GI side effects are the most frequent reason patients discontinue Zepbound. They deserve attention in any safety discussion.

Incidence by Dose

In SURMOUNT-1, nausea affected 24.6% of patients on the 5 mg dose, 26.6% on 10 mg, and 33.3% on 15 mg, compared to 9.5% on placebo. Diarrhea ranged from 17.4% to 23.0% across active doses. Vomiting occurred in 5.8% to 12.8% of tirzepatide-treated patients [4]. Most GI events occurred during the dose-escalation phase (the first 20 weeks) and were mild to moderate in severity.

Dose-Escalation Strategy

The recommended titration schedule starts at 2.5 mg weekly for four weeks, then increases to 5 mg weekly. From there, doses may be increased by 2.5 mg increments at intervals of at least four weeks to the maintenance dose of 5 mg, 10 mg, or 15 mg weekly [1]. Extending the time at each dose step (for example, remaining at 5 mg for eight weeks instead of four before escalating) can reduce the severity of GI side effects in sensitive patients.

Drug Interactions and Special Populations

Tirzepatide slows gastric emptying, which can affect the absorption of concomitant oral medications. This pharmacokinetic property has practical implications for several drug classes.

Oral Contraceptives

The delayed gastric emptying caused by tirzepatide may reduce the efficacy of oral hormonal contraceptives. The FDA label recommends that patients using oral contraceptives switch to a non-oral contraceptive method, or add a barrier method, for four weeks after initiating Zepbound and for four weeks after each dose escalation [1].

Medications with Narrow Therapeutic Windows

Drugs with narrow therapeutic indices that depend on threshold concentrations for efficacy (such as warfarin, levothyroxine, and certain anticonvulsants) should be monitored more closely when co-administered with Zepbound. INR monitoring in warfarin patients and TSH rechecks in levothyroxine patients at 6 to 8 weeks after starting or changing the tirzepatide dose are practical steps [1].

Pregnancy and Lactation

Zepbound is contraindicated in pregnancy. Animal reproduction studies showed adverse developmental effects at clinically relevant exposures [1]. Given the long washout period of tirzepatide (approximately five half-lives, or roughly 25 days), the FDA recommends discontinuing Zepbound at least two months before a planned pregnancy. There are no adequate data on the presence of tirzepatide in human milk.

How Zepbound Compares to Other GLP-1 Receptor Agonists on Safety

The safety profile of tirzepatide shares features with the broader GLP-1 receptor agonist class but has some distinctions worth noting.

Shared Class Warnings

The boxed warning for thyroid C-cell tumors, the pancreatitis warning, and the gallbladder warning appear across GLP-1 receptor agonist labels, including semaglutide (Wegovy, Ozempic), liraglutide (Saxenda), and dulaglutide (Trulicity) [13]. These are considered class effects.

Tirzepatide-Specific Considerations

Tirzepatide is unique in its dual GIP and GLP-1 receptor agonism. Whether GIP receptor activation introduces additional safety signals beyond those of pure GLP-1 agonists remains an area of active investigation. In the SURPASS and SURMOUNT trial programs, no novel organ-toxicity signals emerged that were attributable to GIP agonism specifically [4][14]. The overall discontinuation rate due to adverse events in SURMOUNT-1 was 4.3% for the 5 mg group, 7.1% for 10 mg, and 6.2% for 15 mg, compared to 2.6% for placebo [4].